Abstracts tagged "Gout and registries"

Abstract Number: 2008 • 2013 ACR/ARHP Annual Meeting
Assessing Treat To Target In Gout Patients With and Without Tophi
Leslie R. Harrold¹, Carol Etzel^2,3, Bruce Schechter⁴, Raymond L. Malamet⁵, Vanessa Cox² and Jeffrey D. Greenberg⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²CORRONA, Inc, Southborough, MA, ³Department of Epidemiology, UT MD Anderson, Houston, TX, ⁴Savient Pharmaceuticals, Inc., Bridgewater, NJ, ⁵Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ⁶NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Little is known regarding the differences in characteristics between patients with tophaceous gout compared to those without tophi. We examined these differences in a…
Abstract Number: 1200 • 2013 ACR/ARHP Annual Meeting
Proportion Of Patients Achieving Serum Urate Target In a Longitudinal Veterans Administration (VA) Gout Registry: Crystal Registry
Puja Khanna^1,2, Andreas M. Reimold³, Gail S. Kerr⁴, J. Steuart Richards⁵, Elizabeth Chang⁶, Jasvinder A. Singh⁷, H. Ralph Schumacher⁸, Tanima Bannerjee⁹ and Dinesh Khanna¹⁰, ¹Rheumatology, Ann Arbor VA, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Rheumatology, Washington DC VAMC and Georgetown University, Washington, DC, ⁶Phoenix VAHCS, Phoenix, AZ, ⁷Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁸Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁹Biostatistics, University of Michigan, Ann Arbor, MI, ¹⁰University of Michigan Health System, Ann Arbor, MI
Background/Purpose: Gout is the most common inflammatory arthritis managed by healthcare providers at the VA Healthcare System. CRYSTAL registry is a longitudinal observational study at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].